ArticleMedicine2026
Establishment of a novel gene panel for prognosis assessment in patients with lower grade glioma.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lower-grade gliomas (LGGs) encompass a diverse group of primary brain tumors and are associated with poor survival outcomes, particularly among young adults. This study aimed to develop a novel approach for accurately predicting prognosis in LGG patients.
methodsUsing gene expression and clinical data from The Cancer Genome Atlas and the Chinese Glioma Genome Atlas, we identified and validated genes with prognostic significance. We then constructed a 71-gene prognostic score and developed a corresponding nomogram. These tools were evaluated for their association with overall survival (OS) and relapse-free survival (RFS) in LGG patients. Additionally, hierarchical clustering of the 71 genes was performed to identify distinct patient subgroups with unique clinical characteristics.
resultsThe 71-gene score was found to be a significant and independent predictor of poor OS and RFS in LGG patients, regardless of clinicopathological features. Hierarchical clustering revealed 3 distinct patient subgroups. Notably, tumors in Cluster 2 were characterized by higher tumor grade, more frequent radiation therapy, and worse OS and RFS compared to those in Clusters 1 and 3. Furthermore, the 71-gene nomogram, which incorporates survival-related clinical variables, showed high predictive accuracy for OS and for 3- and 5-year survival rates, with area under the curve values of 0.83, 0.88, and 0.86, respectively.
conclusionsThe 71-gene nomogram shows significant potential to enhance prognostic prediction in LGG, offering a valuable and reliable tool for clinicians and researchers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.